
Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer
HONG KONG,March 17,2025--Akeso Inc. (9926.HK) announced that its innovative,self-developed anti-PD-1 monoclonal antibody,penpulimab,has been officially approved by the National Medical Products Admini